PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF ARQ 087, A NOVEL PAN-FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING INTRAHEPATIC CHOLAN-GIOCARCINOMA.

被引：0
|
作者：
Savage, R. [1 ]
Trinh, M. [2 ]
Dupuis, M. [2 ]
Marier, J. F. [2 ]
Schwartz, B. [1 ]
机构：
[1] ArQule, Burlington, MA USA
[2] Certara Strateg Consulting, Montreal, PQ, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-091
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [31] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [32] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
    Brunetto, Andre T.
    Ang, Joo Ern
    Lal, Rohit
    Olmos, David
    Molife, L. Rhoda
    Kristeleit, Rebecca
    Parker, Ann
    Casamayor, Isabel
    Olaleye, Muyibat
    Mais, Anna
    Hauns, Bernhard
    Strobel, Vera
    Hentsch, Bernd
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504
  • [33] Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors
    Lin, C-C.
    Grewal, J.
    Sommerhalder, D.
    Bai, L-Y.
    Li, G.
    Schneider, R.
    Shen, L.
    Yeh, Y-M.
    Yin, R.
    Hsu, H-C.
    Baranda, J. C.
    Hsieh, C-Y.
    Cai, S. X.
    Tian, Y. E.
    Ma, N.
    Xia, H.
    Zhang, C.
    Li, B.
    Zhang, M.
    Yu, Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S760 - S761
  • [34] Pharmacokinetic and pharmacodynamic effects of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors
    Ricart, A.
    Cooney, M.
    Sarantopoulos, J.
    Brell, J.
    Locke, K.
    Gammans, R.
    Munsey, M.
    Tolcher, A.
    Remick, S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 111 - 112
  • [35] Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors
    Bahleda, Rastislav
    Dienstmann, Rodrigo
    Adamo, Barbara
    Gazzah, Anas
    Infante, Jeffrey R.
    Zhong, Bob
    Platero, Suso J.
    Smit, Hans
    Perera, Timothy
    Stuyckens, Kim
    Bussolari, Jacqueline
    Poddareddigari, Vijay
    Soria, Jean-Charles
    Luo, Feng Roger
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
    Dienstmann, Rodrigo
    Bahleda, Rastilav
    Adamo, Barbara
    Rodon, Jordi
    Varga, Andrea
    Gazzah, Anas
    Platero, Suso
    Smit, Hans
    Perera, Timothy
    Zhong, Bob
    Stuyckens, Kim
    Elsayed, Yusri
    Takimoto, Chris
    Peddareddigari, Vijay
    Tabernero, Josep
    Luo, Feng Roger
    Soria, Jean-Charles
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Tamura, Kenji
    Tanabe, Yuko
    Yonemori, Kan
    Yoshino, Takayuki
    Fuse, Nozomu
    Kodaira, Makoto
    Bando, Hideaki
    Noguchi, Kazuo
    Shimamoto, Takashi
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 409 - 416
  • [39] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Kenji Tamura
    Yuko Tanabe
    Kan Yonemori
    Takayuki Yoshino
    Nozomu Fuse
    Makoto Kodaira
    Hideaki Bando
    Kazuo Noguchi
    Takashi Shimamoto
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 409 - 416
  • [40] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Harding, J.
    Perez, C.
    Kato, S.
    Sharma, M.
    Garmezy, B.
    Quah, C.
    Tam, B.
    Severson, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
12345